NeuroVive Pharmaceutical AB (publ) - amendment number of shares and votes


Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act
(1991:980), the company is hereby reporting that as a result of new share issue
conducted by NeuroVive Pharmaceutical AB (publ) (“NeuroVive”), as resolved by
the Board of Directors on 28 February 2016 and approved by the extraordinary
general meeting on 31 March 2016, the number of shares and votes of NeuroVive
registered with the Swedish Companies Registration Office have increased by
17,984,960. Accordingly, the total number of shares and votes in NeuroVive is
49,458,645.
About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a
company committed to the discovery and development of highly targeted candidates
that preserve mitochondrial integrity and function in areas of significant
therapeutic need. NeuroVive’s business approach is driven by value-adding
partnerships with mitochondrial research institutions and commercial partners
across the globe. NeuroVive’s portfolio consists of two clinical projects in
acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in
clinical and preclinical development and two drug discovery platforms. The
NeuroSTAT® product has orphan drug status in Europe and in the US for treatment
of moderate to severe traumatic brain injury and is currently being evaluated in
a study, CHIC. Ciclosporin (CicloMulsion®) is being evaluated in an on-going
study, CiPRICS, in acute kidney injury during major surgery. NeuroVive’s shares
are listed on Nasdaq, Stockholm, Sweden.

For investor relations and media questions, please contact:
Christine Tadgell, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.com, www.neurovive.com

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on the 31 May 2016, at 08.45 CET.
NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The
company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol
NVP. The share is also traded on the OTC market in the US. NeuroVive
Pharmaceutical (OTC: NEVPF) trades on the OTC Pink Market. Investors can find
Real-Time quotes and market information for the company
at  www.otcmarkets.com/stock/NEVPF/quote (http://htt//www.otcmarkets.com/stock/N
E 
VPF/quot)

Attachments

05300320.pdf